0001415889-24-015587.txt : 20240605 0001415889-24-015587.hdr.sgml : 20240605 20240605165742 ACCESSION NUMBER: 0001415889-24-015587 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wassil Jim CENTRAL INDEX KEY: 0001813798 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 241022772 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 353 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 form4-06052024_080638.xml X0508 4 2024-06-03 0001649094 Vaxcyte, Inc. PCVX 0001813798 Wassil Jim C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 false true false false CHIEF OPERATING OFFICER 1 Common Stock 2024-06-03 4 S 0 1634 71.384 D 214869 D Common Stock 2024-06-03 4 S 0 906 72.319 D 213964 D Common Stock 2024-06-03 4 S 0 460 73.475 D 213503 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $70.98 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024. The price reported is a weighted-average price. The shares were sold at prices ranging from $72.01 to $72.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $73.41 to $73.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Ron A. Metzger, Attorney-in-Fact 2024-06-05